GARDEN (Global Hematological Rare Diseases Alliance)/LinkedIn
May 23, 2026, 14:42
How Should Evidence Be Interpreted in Modern Hemophilia Care? – GARDEN
GARDEN (Global Hematological Rare Diseases Alliance) shared a post on LinkedIn:
“How should evidence be interpreted in modern hemophilia care?
In this new contribution from the GARDEN editorial series, Prof. Cedric Hermans explores the methodological debate behind international hemophilia guidelines, examining the balance between randomized clinical trials, real-world evidence, and patient-centered decision-making.
A critical reflection on how evidence shapes clinical practice, access to care, and the future of hemophilia management.”
Stay updated with Hemostasis Today.
-
Aug 31, 2026, 05:35Does LDL Cholesterol Influence VTE Risk? – Ordo Fraterna Fibonacci
-
Aug 31, 2026, 05:19Tania Ahuja: Apixaban in Abdominal Transplant Patients
-
Aug 31, 2026, 04:28Reza Hafidz Irawan։ Automated Antibody Titration With Erytra Eflexis
-
Aug 31, 2026, 04:17Safa Chenganath: Stenosis vs Thrombosis – Hemodialysis Vascular Access
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session